Innovation Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPIX research report →
Price Chart
About the company
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions.
- CEO
- Leo Ehrlich
- IPO
- 2007
- Employees
- 4
- HQ
- Wakefield, MA, US
Get TickerSpark's AI analysis on IPIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.35M
- P/E
- -0.41
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.64
- EV/EBITDA
- -0.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -93.60%
- ROIC
- -112.55%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-373,000-2172.2%
- Op Income
- $-3,111,000
- Net Income
- $-3,168,000+55.0%
- EPS
- $-0.01+55.0%
- OCF Growth
- +66.5%
- FCF Growth
- +65.9%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.49
- RSI (14)
- 47
- Avg Volume
- 220.16K
No earnings-call transcripts are available for IPIX yet.
- Free Float
- 99.2%
- Shares Outstanding
- 518.35M
- Float Shares
- 514.10M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kingfisher Capital LLC | 11.00K | ▲ 11.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 30, 22 | EHRLICH LEO | other | 11,307,527 |
| Oct 10, 21 | Harness Jane A. | other | 500,000 |
| Sep 11, 20 | Harness Jane A. | other | 58,394 |
| Sep 1, 19 | Harness Jane A. | other | 58,394 |
| Sep 11, 20 | Harness Jane A. | other | 21,606 |
| Sep 1, 19 | Harness Jane A. | other | 172,987 |
| Sep 11, 20 | Harness Jane A. | other | 172,987 |
| Sep 1, 17 | Harness Jane A. | other | 1,000 |
| Oct 10, 21 | Schechter Barry A | other | 1,000,000 |
| Feb 23, 20 | Schechter Barry A | other | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IPIX coverage
Recent articles, reports, and earnings notes.
No research on IPIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPIX report →Innovation X Advisors Participates in Shield AI's $1.5 Billion Series G Financing
businesswire.com · Jul 29
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
prnewswire.com · Jun 22
INVNT™ Announced as Sponsor and Co-Producer of Discovery Stage at SXSW Sydney® 2024
https://www.businesswire.com · May 20
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
globenewswire.com · Aug 28
Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium
globenewswire.com · Jun 18
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
globenewswire.com · May 27
Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19
globenewswire.com · Apr 28
Innovation Pharma's Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation
globenewswire.com · Apr 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.